A multinational phase 2 trial (ALTA-2, NCT03535740) has enrolled 104 patients to investigate brigatinib efficacy and safety in patients with ALK+ NSCLC in the post-alectinib or post-ceritinib setting.33 Here, ALK is linked to non-small cell lung carcinoma.